Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
999999 participants
OBSERVATIONAL
2013-11-01
2099-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Registry of Oncology Outcomes Associated with Testing and Treatment
NCT04028479
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
NCT00026884
Inherited CAncer REgistry
NCT03231891
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069
Rare CNS Tumors Outcomes &Risk
NCT03251989
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The iCaRe2 has been developed as an expansion of the biocomputing framework that initially included four multi-center collaborative registries: Pancreatic Cancer Collaborative Registry (PCCR), Breast Cancer Collaborative Registry (BCCR), Thyroid Cancer Collaborative Registry (TCCR), and Great Plains Health Informatics Database (GPHID; to enroll subjects with no history of cancer diagnosis at time of enrollment). The repository now includes: Thoracic Oncology Collaborative Registry (TOCR), GenitoUrinary Cancer Collaborative Registry (GUCARE), Head and Neck Cancer Collaborative Registry (HNCCR), Gastrointestinal \& Abdominal Cavity Cancer Collaborative Registry (GACCaRe), Central Nervous System Tumor Collaborative Registry (CTCR), Leukemia and Myeloid Neoplasm Registry (LEMN) , Gynecological Cancer Collaborative Registry (GCCR), Sarcoma Collaborative Registry (SARCR), Melanoma Collaborative Registry (MELCR), Plasma Cell Dyscrasias Collaborative Registry (PDCR), Neuroendocrine Collaborative Registry (NETR), Non-Melanoma Skin Cancer Registry (NMSC) and Auxiliary Cancer Registry (ACR).
The iCaRe2 group elected to use a "confederation model", as opposed to a traditional registry or network model. The major advantages of a confederation model include the flexibility to use selected Centers for different research projects based on a Center's resources and expertise and the ability to have different strategies to address various research questions. A web-based registry iCaRe2 was developed and made available to any Center to participate in data collection and storage of cancer related data. The iCaRe2 provides a HIPAA compliant, secure, efficient and user-friendly mechanism for data and validation; utilization of standard vocabulary and data elements; and ad-hoc data reporting capabilities. The iCaRe2 serves as a collaboration platform for studies (including clinical trials) performed in centers with expertise in cancer biology, pathology, epidemiology, genetics, early detection, and patient care.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Risk for developing cancer or suspicious clinical findings
* No history of cancer (normal control registry)
* Able to provide informed consent
* 19 years of age or older
* English or Spanish speaking individuals
Exclusion Criteria
* Non-English or non-Spanish speaking individuals
19 Years
110 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Nebraska
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kurt Fisher, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Nebraska
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Advent Health
Greenwood Village, Colorado, United States
Prospect Medical Hospital
Manchester, Connecticut, United States
Florida Hospital Memorial Medical Center
Daytona Beach, Florida, United States
Florida Hospital DeLand
DeLand, Florida, United States
Florida Hospital FISH
Orange City, Florida, United States
Florida Hospital Flagler
Palm Coast, Florida, United States
Tallahassee Memorial Hospital
Tallahassee, Florida, United States
Rush-Copley Cancer Care Center
Aurora, Illinois, United States
Rush-Copley Healthcare Center
Yorkville, Illinois, United States
Parkview Research Center
Fort Wayne, Indiana, United States
Methodist Jennie Edmundson Hospital
Council Bluffs, Iowa, United States
Covenant Medical Center, Inc
Waterloo, Iowa, United States
Saint Luke's Cancer Instititute - South
Overland Park, Kansas, United States
Northwest Hospital
Randallstown, Maryland, United States
William E. Kahlert Regional Cancer Center
Westminster, Maryland, United States
Holyoke Medical Center
Holyoke, Massachusetts, United States
University of Michigan Health System
Ann Arbor, Michigan, United States
Riverwood Healthcare Center
Aitkin, Minnesota, United States
Essentia Health-St. Joseph's Medical Center
Brainerd, Minnesota, United States
Essentia Health - Duluth Clinic
Duluth, Minnesota, United States
St. Luke's Hospital of Duluth
Duluth, Minnesota, United States
Lake Region Healthcare
Fergus Falls, Minnesota, United States
Saint Luke's Cancer Institute, East
Kansas City, Missouri, United States
Saint Luke's Cancer Institute
Kansas City, Missouri, United States
Saint Luke's Cancer Institute, Kansas City North
Kansas City, Missouri, United States
Saint Luke's Cancer Institute, Liberty
Liberty, Missouri, United States
North Kansas City Hospital
North Kansas City, Missouri, United States
Heartland Regional Medical Center dba Mosaic Life Care
Saint Joseph, Missouri, United States
Bozeman Health Deaconess Hospital
Bozeman, Montana, United States
Mary Lanning Healthcare, Morrison Cancer Center
Hastings, Nebraska, United States
Faith Regional Health Services, Carson Cancer Center
Norfolk, Nebraska, United States
Great Plains Regional Medical Center
North Platte, Nebraska, United States
Methodist Estabrook Cancer Center
Omaha, Nebraska, United States
Nebraska Methodist Health System
Omaha, Nebraska, United States
University of Nebraska Medical Center
Omaha, Nebraska, United States
C.R. Wood Cancer Center, Glens Falls Hospital
Glens Falls, New York, United States
Faxton St. Luke's Healthcare, Mohawk Valley
Utica, New York, United States
Cape Fear Valley Health System
Fayetteville, North Carolina, United States
Essentia Health
Fargo, North Dakota, United States
Trinity Hospital Cancer Care Center
Minot, North Dakota, United States
Aultman Alliance Community Hospital
Alliance, Ohio, United States
Aultman Hospital
Canton, Ohio, United States
University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Rutland Regional Medical Center
Rutland, Vermont, United States
Bellin Memorial Hospital
Green Bay, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Michael Zlomke, MD
Role: primary
Russell Smith, MD
Role: primary
Aqeel Gillani, MD
Role: backup
Kenneth Manning, MD
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
icare2 website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0253-13-EP
Identifier Type: -
Identifier Source: org_study_id
NCT00693368
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.